BioTime, Inc Stock News

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest I

NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that c

Looking to roll the dice? Consider buying one (or more) of these seven high-risk, but possibly high-return, Reddit stocks.

The biotech is bulking up with a new acquisition.

Brooklyn ImmunoTherapeutics LLC (NYSE: BTX) has executed a non-binding letter of intent to acquire Novellus Therapeutics, a company developing engineered mesenchymal stem cell (MSC) therapies using

Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies Novellus Therapeutics develops next-generati

BROOKLYN, N.Y., June 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene

BROOKLYN, N.Y., June 08, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) ("Brooklyn"), a biopharmaceutical company focused on exploring the role that cytokine and gene

BTX stock holders will certainly want to brace for volatility. Still, the outlook's bullish as the company pursues its game-changing research.

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Company's Future During May 25, 2021 Shareholder Update Call

The stock price of Brooklyn Immunotherapeutics Inc (NYSEAMERICAN: BTX) increased by 21.02% today. This is why it happened.

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing

BROOKLYN, N.Y.--(BUSINESS WIRE)--Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc.

Is change at the C-suite level a good thing for a company? The facts seem to indicate that it's a positive development for BTX stock holders.

BROOKLYN, N.Y.--(BUSINESS WIRE)--Brooklyn ImmunoTherapeutics announces the appointment of Christopher Rohde, Ph.D. to the Company's Scientific Advisory Board